Lucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology
Lucid Diagnostics (LUCD) has launched the 'Embrace the Future' campaign to highlight its EsoCheck® Esophageal Cell Collection Device with Collect+Protect™ Technology. The campaign will be featured during Esophageal Cancer Awareness Month in April and at the Digestive Disease Week 2025 conference in May.
EsoCheck has demonstrated exceptional performance across nearly 30,000 patients, featuring high patient satisfaction, a perfect safety record, and efficient three-minute procedures in office settings. When combined with Lucid's EsoGuard® Esophageal DNA Test, the technology achieved a remarkable 99% negative predictive value in detecting esophageal precancer.
The company emphasizes EsoCheck's advantages over traditional sponge-on-a-string (SOS) devices, highlighting its precise targeting capabilities and protected sampling approach, contrasting with SOS devices' limitations and history of FDA recalls.
Lucid Diagnostics (LUCD) ha lanciato la campagna 'Abbraccia il Futuro' per mettere in evidenza il suo Dispositivo di Raccolta Cellulare EsoCheck® con Tecnologia Collect+Protect™. La campagna sarà presentata durante il mese di sensibilizzazione sul cancro esofageo in aprile e alla conferenza Digestive Disease Week 2025 in maggio.
EsoCheck ha dimostrato prestazioni eccezionali su quasi 30.000 pazienti, con un elevato grado di soddisfazione dei pazienti, un perfetto record di sicurezza e procedure efficienti di tre minuti in contesti ambulatoriali. Quando combinato con il test del DNA esofageo EsoGuard® di Lucid, la tecnologia ha raggiunto un notevole valore predittivo negativo del 99% nella rilevazione del precancro esofageo.
L'azienda sottolinea i vantaggi di EsoCheck rispetto ai tradizionali dispositivi a spugna su un filo (SOS), evidenziando le sue capacità di targeting preciso e l'approccio di campionamento protetto, in contrasto con le limitazioni e la storia di richiami FDA dei dispositivi SOS.
Lucid Diagnostics (LUCD) ha lanzado la campaña 'Abraza el Futuro' para resaltar su Dispositivo de Recolección de Células EsoCheck® con Tecnología Collect+Protect™. La campaña se presentará durante el Mes de Concienciación sobre el Cáncer Esofágico en abril y en la conferencia Digestive Disease Week 2025 en mayo.
EsoCheck ha demostrado un rendimiento excepcional en casi 30,000 pacientes, con una alta satisfacción del paciente, un historial de seguridad perfecto y procedimientos eficientes de tres minutos en entornos de consultorio. Cuando se combina con la Prueba de ADN EsoGuard® de Lucid, la tecnología logró un notable valor predictivo negativo del 99% en la detección de precáncer esofágico.
La empresa enfatiza las ventajas de EsoCheck sobre los dispositivos tradicionales de esponja en un hilo (SOS), destacando sus capacidades de apuntado preciso y su enfoque de muestreo protegido, en contraste con las limitaciones y la historia de retiros de la FDA de los dispositivos SOS.
Lucid Diagnostics (LUCD)는 EsoCheck® 식도 세포 수집 장치와 Collect+Protect™ 기술을 강조하기 위해 '미래를 포용하라' 캠페인을 시작했습니다. 이 캠페인은 4월의 식도암 인식의 달과 5월의 소화기 질환 주간 2025 컨퍼런스에서 소개될 예정입니다.
EsoCheck는 거의 30,000명의 환자에서 뛰어난 성능을 입증했으며, 높은 환자 만족도, 완벽한 안전 기록 및 사무실 환경에서의 효율적인 3분 절차를 특징으로 합니다. Lucid의 EsoGuard® 식도 DNA 테스트와 결합했을 때, 이 기술은 식도 전암을 탐지하는 데 있어 놀라운 99%의 음성 예측 가치를 달성했습니다.
회사는 EsoCheck의 전통적인 스폰지-스트링(SOS) 장치에 대한 장점을 강조하며, 정확한 타겟팅 능력과 보호된 샘플링 접근 방식을 강조하고, SOS 장치의 한계와 FDA 리콜 이력을 대조하고 있습니다.
Lucid Diagnostics (LUCD) a lancé la campagne 'Embrasser l'Avenir' pour mettre en avant son Dispositif de Collecte de Cellules EsoCheck® avec la Technologie Collect+Protect™. La campagne sera présentée durant le Mois de Sensibilisation au Cancer de l'Oesophage en avril et lors de la conférence Digestive Disease Week 2025 en mai.
EsoCheck a démontré des performances exceptionnelles auprès de près de 30 000 patients, avec une grande satisfaction des patients, un dossier de sécurité parfait et des procédures efficaces de trois minutes en cabinet. Lorsqu'il est associé au test ADN EsoGuard® de Lucid, la technologie a atteint une valeur prédictive négative remarquable de 99 % dans la détection des précancers de l'œsophage.
L'entreprise souligne les avantages d'EsoCheck par rapport aux dispositifs traditionnels à éponge sur une corde (SOS), mettant en avant ses capacités de ciblage précis et son approche de prélèvement protégé, en contraste avec les limitations et l'historique des rappels de la FDA des dispositifs SOS.
Lucid Diagnostics (LUCD) hat die Kampagne 'Umarmen Sie die Zukunft' ins Leben gerufen, um sein EsoCheck® Speiseröhrenzellen-Sammelgerät mit Collect+Protect™ Technologie hervorzuheben. Die Kampagne wird während des Monats zur Sensibilisierung für Speiseröhrenkrebs im April und auf der Konferenz Digestive Disease Week 2025 im Mai präsentiert.
EsoCheck hat in fast 30.000 Patienten außergewöhnliche Leistungen gezeigt, mit hoher Patientenzufriedenheit, einer perfekten Sicherheitsbilanz und effizienten dreiminütigen Verfahren in Praxen. In Kombination mit Lucids EsoGuard® Speiseröhren-DNA-Test erreichte die Technologie einen bemerkenswerten negativen prädiktiven Wert von 99% bei der Erkennung von Speiseröhrenvorstufen.
Das Unternehmen betont die Vorteile von EsoCheck gegenüber traditionellen Schwamm-an-Schnur (SOS) Geräten und hebt die präzisen Zielmöglichkeiten und den geschützten Probenahmeansatz hervor, im Gegensatz zu den Einschränkungen und der Geschichte von FDA-Rückrufen der SOS-Geräte.
- EsoCheck demonstrated 99% negative predictive value in detecting esophageal precancer
- Successfully performed nearly 30,000 procedures with perfect safety record
- Efficient 3-minute procedure completion in office settings
- High patient satisfaction rates reported
- None.
Campaign will coincide with Esophageal Cancer Awareness Month and will be featured at the upcoming Digestive Disease Week (DDW) Conference
The campaign highlights EsoCheck's outstanding performance in nearly 30,000 patients to date, including a pristine safety record, high patient satisfaction, and a very high success rate for a procedure performed in an office or health fair setting in less than three minutes. Published data demonstrates that samples collected with EsoCheck, when analyzed with Lucid's EsoGuard® Esophageal DNA Test, detected esophageal precancer, including short segment disease, with an unprecedented negative predictive value (NPV) of approximately
"April is Esophageal Cancer Awareness Month, a sober reminder that approximately 16,000 Americans tragically die each year from this highly lethal, but now preventable, cancer," said Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer. "Thanks to our modern groundbreaking technologies, EsoGuard and EsoCheck, the future for esophageal cancer prevention is very bright. A substantial body of published, peer-reviewed clinical evidence now demonstrates EsoGuard's unprecedented performance as a noninvasive triage tool to detect esophageal precancer so it can be monitored and treated before cancer develops. EsoCheck's ability to perform precisely targeted and protected sampling plays a critical role in this outstanding performance."
Dr. Aklog added, "Brillo pad-like sponge-on-a-string (SOS) devices, essentially unchanged in design since they were introduced in the early 1990s, are relics of the past which indiscriminately scrape cells from the stomach, esophagus and mouth. Their poor performance, especially in patients with small patches of precancer, is attributable to their inability to target the specific area of the esophagus where precancer and cancer occur. SOS devices have also been plagued by serious device failures and complications, leading to multiple Class II FDA recalls and product withdrawals. In stark contrast, EsoCheck's soft and gentle, targeted and protected approach to noninvasive esophageal cell collection has resulted in a pristine safety record with no device failures after nearly 30,000 procedures."
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information about Lucid, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-launches-embrace-the-future-campaign-showcasing-esochecks-groundbreaking-collectprotect-esophageal-cell-collection-technology-302413105.html
SOURCE Lucid Diagnostics
FAQ
What is the success rate of Lucid Diagnostics' EsoCheck device in detecting esophageal precancer?
How many procedures has LUCD's EsoCheck device completed successfully?
How long does the LUCD EsoCheck procedure take to complete?
When will Lucid Diagnostics showcase its EsoCheck device at DDW 2025?
How does LUCD's EsoCheck differ from traditional sponge-on-a-string devices?
